Cipla Limited is India's third-largest pharmaceutical company by revenue — approximately $2.9 billion globally (FY25). But its most important competitive advantage is not its size or its global reach: it is its respiratory portfolio, which generates 25%+ of India revenues and has been the foundation of Cipla's brand equity for over three decades.
Why Respiratory Is a Moat Business
Generic pharmaceuticals are typically commoditised — once a drug's patent expires, multiple manufacturers copy the molecule and compete on price. Inhalers are structurally different. An inhaler is a combination of a drug (the active molecule) and a device (the delivery mechanism). Regulatory agencies require approval of both — the drug must be bioequivalent to the innovator, AND the device must be approved as safe and effective. This dual requirement means the regulatory barrier is significantly higher than for oral generics. Cipla has spent 30 years optimising its inhaler devices and manufacturing processes — creating institutional knowledge that is difficult to replicate quickly.
Africa: The Hidden Growth Driver
Cipla's sub-Saharan Africa business — particularly South Africa, where it is the #1 pharma by prescription value — contributes approximately 15% of global revenue and grows at 12-15% annually. Africa's healthcare penetration is rising rapidly, branded generics command premium pricing, and Cipla's 30-year presence in the region creates distribution relationships that new entrants cannot match in years.
- India respiratory revenue: ~25% of India total (₹3,500+ crore)
- Key brands: Asthalin (#1 salbutamol inhaler), Foracort, Seroflo
- Africa revenue: ~15% of global total, growing 12-15%
- US business: focused on complex generics and inhalation products
- Consolidated EBITDA margin: ~22-24%
🔍 BBS Insight
Cipla's valuation (25-28x earnings) is partially supported by its respiratory moat — but the full bull case requires US inhalation approvals to materialise (Cipla has been navigating FDA challenges on its US inhaler filings for years). Track two things: (1) India respiratory growth vs IMS market data — if Cipla is growing faster than the market, the moat is strengthening; (2) US inhalation ANDA approvals — each approval represents a meaningful US revenue step-up. When both are positive simultaneously, the re-rating potential is significant.